نتایج جستجو برای: early virologic response

تعداد نتایج: 1595197  

Journal: :Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007
Pratima Sharma Jorge A Marrero Robert J Fontana Joel K Greenson Hari Conjeevaram Grace L Su Frederick Askari Patricia Sullivan Anna S Lok

Sustained virologic response (SVR) after antiviral therapy for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients is consistently lower than that achieved in non-LT patients. We evaluated efficacy and safety of pegylated interferon (IFN) and ribavirin (RBV) therapy in LT recipients with recurrent HCV and factors associated with SVR. All subjects with histologic evid...

2013
Yidan Lu Anton Andonov David K. H. Wong

24 Hepatitis C (HCV) viremia is unusual (<5%) after successful treatment, defined as sustained 25 virologic response (SVR) or undetectable HCV PCR 12-24 weeks after therapy. We present a 26 case of late virologic relapse (de novo infection excluded by RNA sequencing) after SVR 27 followed by spontaneous viral clearance. 28

Journal: :Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2010
Tetsuo Takehara

Antiviral therapy for chronic hepatitis C has advanced dramatically since the discovery of the hepatitis C virus and the introduction of interferon in early 1990's. An initial treatment regimen, 24 weeks of interferon monotherapy, achieved sustained virologic response, which is formally defined at 24 weeks after completion of the treatment, only for 5% of patients with genotype 1 high-viral loa...

Journal: :The New England journal of medicine 2014
Kris V Kowdley Stuart C Gordon K Rajender Reddy Lorenzo Rossaro David E Bernstein Eric Lawitz Mitchell L Shiffman Eugene Schiff Reem Ghalib Michael Ryan Vinod Rustgi Mario Chojkier Robert Herring Adrian M Di Bisceglie Paul J Pockros G Mani Subramanian Di An Evguenia Svarovskaia Robert H Hyland Phillip S Pang William T Symonds John G McHutchison Andrew J Muir David Pound Michael W Fried

BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. This study examined 8 weeks of treatment with this regimen. METHODS In this phase 3, open-label study, we randomly assigned 647 previously un...

Journal: :Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2015
Sergio Iannazzo Piero Colombatto Gabriele Ricco Filippo Oliveri Ferruccio Bonino Maurizia R Brunetto

BACKGROUND AND AIMS Rapid virologic response is the best predictor of sustained virologic response with dual therapy in genotype-1 chronic hepatitis C, and its evaluation was proposed to tailor triple therapy in F0-F2 patients. Bio-mathematical modelling of viral dynamics during dual therapy has potentially higher accuracy than rapid virologic in the identification of patients who will eventual...

Journal: :Journal of clinical microbiology 2014
Yidan Lu Anton Andonov David K H Wong

Hepatitis C virus (HCV) viremia is unusual (<5%) after successful treatment, defined as sustained virologic response (SVR) or undetectable HCV PCR 12 to 24 weeks after therapy. We present a case of late virologic relapse (de novo infection was excluded by RNA sequencing) after SVR followed by spontaneous viral clearance.

Journal: :AIDS 2014
Heidi M Soeters Sonia Napravnik Monita R Patel Joseph J Eron Annelies Van Rie

OBJECTIVE To determine the impact of tuberculosis (TB) treatment at the time of combination antiretroviral therapy (cART) initiation on virologic and CD4 cell count response to cART. METHODS Systematic review and meta-analysis of studies reporting HIV RNA and CD4 cell count response, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-regression analyses w...

Journal: :Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 2014
Carmen Monica Preda Cristian Baicus Lucian Negreanu Letitia Tugui Sandra Viviana Olariu Adriana Andrei Ileana Zambatu Mircea Mihai Diculescu

INTRODUCTION Entecavir (ETV) is a potent inhibitor of hepatitis B virus (HBV) replication. In patients adherent to treatment, virologic remission rates of > 95 % can be maintained with entecavir at 3-5 years. AIM AND METHODS A cohort study was performed, including all subjects who received ETV for chronic hepatitis B, in the South- Eastern Romania. We assessed viral response, HBeAg loss and s...

Journal: :avicenna journal of clinical microbiology and infection 0
peyman eini brucellosis research centre, department of infectious diseases, hamadan university of medical sciences, hamadan, iran mojgan mamani department of infectious diseases, hamadan university of medical sciences, hamadan, iran; brucellosis research centre, sina hospital, mirzadeh-eshghi street, hamadan 65168, iran. tel: +98-8138274192, fax: +98-8138276010 fatemeh keshavarz general practitioner, hamadan university of medical sciences, hamadan, iran abbas moradi department of community medicine, hamadan university of medical sciences, hamadan, iran

objectives the main goal of the treatment of the hepatitis c virus (hcv) infection is reduction and elimination of viruses as well as achieving high sustained viral response (svr). the present study aimed to assess response to treatment of hcv infection by focusing on virological and biochemical aspects. methods this study was performed in hamadan, iran on hcv infected patients who were referre...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید